A Phase 2 trial met its endpoint. The FDA granted Breakthrough Therapy status. A drug candidate is moving toward postpartum depression faster than almost anything else in psychiatry right now. Meanwhile, the most rigorous evidence available on what psychedelics actually do to the postpartum body and a nursing infant comes from a single mouse study, and it found something the field's current pace does not yet reckon with.
By Behavioral Wire Staff · August 4, 2026 · 9 min
A bill to fund the perinatal mental health workforce has sat in committee for over a year while the state's 2024 screening mandate keeps identifying more people who need care. Screening and drug approval both assume a trained clinician exists on the other end. Massachusetts's own numbers say that assumption doesn't hold, and workforce funding deserves the same urgency as everything built on top of it.
By Behavioral Wire Staff · July 28, 2026 · 7 min
A patented, FDA-track product moving through Lilly-scale pharma capital. A licensed-facilitator service model built entirely outside the FDA. A capped state clinical pilot. A federal access program that fixed its supply chain by narrowing who gets through. These are not four routes to the same destination. They are becoming different products, for different patients, at different prices, and the field's habit of discussing psychedelic access as a single question is obscuring that rather than clarifying it.
By Behavioral Wire Staff · July 25, 2026 · 8 min
Final guidance, a public hearing, an interagency MOU, a state pilot program, new federal funding, all inside a matter of weeks. None of it resolves a single one of the open scientific questions this desk has spent the year tracking. Readers, sponsors, and investors who read process speed as scientific validation are making the same mistake the field has made before, with the same likely outcome.
By Behavioral Wire Staff · July 15, 2026 · 7 min
ACADIA's deuterated ketamine metabolite, Helus Pharma's deuterated psilocin, and the entire esketamine franchise are the same move: take a known psychoactive molecule and re-engineer its pharmacokinetics. The mechanism stopped being the contest. Deployability is.
By Behavioral Wire Staff · June 10, 2026 · 5 min
The voucher list does the talking. The same FDA that issued the Lykos CRL still issued the vouchers, and it sent them to programs whose methods it considers defensible. Sponsors who hear political acceleration as scientific accommodation will misread it as the field misread the original draft guidance, and pay the same kind of price.
By Behavioral Wire Staff · May 29, 2026 · 6 min